Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Change in Account Payables (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Change in Account Payables for 11 consecutive years, with $87.2 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 19.22% to $87.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $79.8 million through Dec 2025, down 34.29% year-over-year, with the annual reading at $79.8 million for FY2025, 34.29% down from the prior year.
  • Change in Account Payables for Q4 2025 was $87.2 million at BeOne Medicines, up from $28.5 million in the prior quarter.
  • The five-year high for Change in Account Payables was $108.0 million in Q4 2024, with the low at -$73.2 million in Q1 2021.
  • Average Change in Account Payables over 5 years is $11.9 million, with a median of $8.0 million recorded in 2022.
  • Peak annual rise in Change in Account Payables hit 1192.5% in 2024, while the deepest fall reached 337.19% in 2024.
  • Over 5 years, Change in Account Payables stood at $32.4 million in 2021, then plummeted by 126.42% to -$8.6 million in 2022, then dropped by 15.51% to -$9.9 million in 2023, then surged by 1192.5% to $108.0 million in 2024, then decreased by 19.22% to $87.2 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $87.2 million, $28.5 million, and -$4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.